8704.5000 103.50 (1.20%)
NSE Mar 06, 2026 15:52 PM
Volume: 3,424
 

8704.50
1.20%
AstraZeneca covid-19 antibody treatment suffers setback
livemint
Drug's efficacy as post-infection therapy falls short in clinical trial, but potential preventative use is still undergoing testing
More from AstraZeneca Pharma India Ltd.
Recommended